By providing up to 60 times more surface area for cell growth than conventional systems, Cellevat3d nanofibre microcarriers increase yield and productivity in upstream bioprocessing of gene therapy applications.
Engineered for stirred tank bioreactors, Cellevat3d nanofibre microcarriers support a wide range of upstream bioprocessing applications including gene therapy, pluripotent stem cell (PSC) expansion, organoid formation, HEK-based recombinant proteins and HEK-based vaccine production.
“Scalable, sustainable and single use, Cellevat3d nanofibre microcarriers closely mimic the human extracellular environment, providing higher cell densities and enhancing yield for viral vector production compared to current standard microcarriers based processes,” says Laura Chirica (pictured), PhD, CEO, of Cellevate.
“Our nanofibre microcarriers effectively address the key challenges of low productivity and high manufacturing costs facing the industry. With this prelaunch of Cellevat3d nanofibre microcarriers starter pack, at CPHI Milan, we’re excited to provide early access to a completely new category of cell culture systems currently unavailable on the market."
"Cellevat3d nanofibre-based cell culture systems truly have the potential to transform biomanufacturing for advanced therapies and take a significant step toward making these therapies more accessible to patients.”